Literature DB >> 3395665

Single-dose pharmacokinetics of terodiline, including a stable isotope technique for improvement of statistical evaluations.

B Hallén1, O Guilbaud, S Strömberg, B Lindeke.   

Abstract

A bioequivalence study with terodiline (Mictrol) was performed in 8 healthy volunteers given a 25 mg oral dose of either of two solid dosage forms together with a water solution of the deuterated drug. The solid dosage forms were found to be bioequivalent. Moreover, their pharmacokinetic profiles were the same as for the water solution. The basic pharmacokinetic parameters (means +/- SE) of terodiline were calculated to: biological half-life in serum 60 +/- 4 h, maximum serum concentration 79 +/- 4 micrograms l-1 and the corresponding time 4 +/- 1 h, oral serum clearance 75 +/- 7 ml min-1, urinary excretion 15.3 +/- 1.5 per cent of dose, and renal serum clearance 10.9 +/- 2.2 ml min-1. The within-subject variability (serum-derived parameters) was about 8 per cent (CV per cent) and the between-subject variation 2-4 times higher. A single parameter estimate in subjects of a comparative population can be expected to show a 3-fold variation (95 per cent confidence). The deuterated drug could be used as a covariate to increase the power/precision in the statistical evaluation of the bioequivalence. In that way the 95 per cent confidence interval for the difference between the formulations, as well as the difference that could be detected with 80 per cent power, was reduced 2- to 5-fold. The covariate method was thus in this respect extremely efficient. In bioequivalence studies with drugs where a large number of subjects would be needed using conventional statistical analyses, this method also offers a possibility to considerably reduce the size of the panel, while retaining sufficient power and precision in the estimates.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3395665     DOI: 10.1002/bod.2510090302

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  8 in total

1.  Population characteristics of biological systems influenced by multicomponent random and uniform variation.

Authors:  G M Kochak
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

Review 2.  Stable isotopes in clinical pharmacokinetic investigations. Advantages and disadvantages.

Authors:  T R Browne
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

3.  Single- and multiple-dose pharmacokinetics of terodiline in geriatric patients.

Authors:  B Hallén; A Magnusson; S Bogentoft; P Ekelund
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Applications of stable isotopes in clinical pharmacology.

Authors:  Reinout C A Schellekens; Frans Stellaard; Herman J Woerdenbag; Henderik W Frijlink; Jos G W Kosterink
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

Review 5.  Genomic architecture of pharmacological efficacy and adverse events.

Authors:  Aparna Chhibber; Deanna L Kroetz; Kelan G Tantisira; Michael McGeachie; Cheng Cheng; Robert Plenge; Eli Stahl; Wolfgang Sadee; Marylyn D Ritchie; Sarah A Pendergrass
Journal:  Pharmacogenomics       Date:  2014-12       Impact factor: 2.533

6.  Use of stable isotopes for evaluation of drug delivery systems: comparison of ibuprofen release in vivo and in vitro from two biphasic release formulations utilizing different rate-controlling polymers.

Authors:  D L Theis; L J Lucisano; G W Halstead
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

Review 7.  Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence.

Authors:  H D Langtry; D McTavish
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

8.  Tolerability and steady-state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinence.

Authors:  B Hallén; S Bogentoft; S Sandquist; S Strömberg; G Setterberg; E Ryd-Kjellén
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.